THE BIOLOGICAL BASIS OF MEDICAL-TREATMENT OF ENDOMETRIOSIS

被引：8

作者：

VENTURINI, PL

SEMINO, A

DECECCO, L

机构：

[1] Department of Gynecology and Obstetrics, University of Genoa School of Medicine, Genoa

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1995年 / 9卷 / 03期

关键词：

ENDOMETRIOSIS; HORMONAL THERAPY; HORMONES; IMMUNE SYSTEM;

D O I：

10.3109/09513599509160455

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Efficacy of medical treatment for the management of endometriosis has been documented in several trials, but clinical results cannot always be maintained after the suspension of treatment. Surgical treatment, either laparotomic or laparoscopic, is affected by tip to 20% in the recurrence of clinical symptoms after long-term follow-up. The appearance of endometriosis is heterogeneous, its functional status is variable and could lack hormone responsiveness. After medical, surgical or combined treatment the persistence of the failure of defence mechanisms accounts for the recurrence of disease. Unfortunately, all schemes to classify stages of endometriosis have so far failed to identify manifestations of the disease that respond in a predictable way to specific treatments. An analysis of the morphological appearance, implant biological activity and immune system involvement might better define the roles for medical management of endometriosis.

引用

页码：259 / 266

页数：8

共 43 条

[11]

Fedele L., Bianchi S., Viezzoli T., Arcaini L., Candiani G.B., Gestrinone versus danazol in the treatment of endometriosis, Fertil. Steril, 51, pp. 781-785, (1989)

[12]

Venturini P.L., Fasce V., Costantini S., Anserini P., Cucuccio S., de Cecco L., Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results, Fertil. Steril, 54, pp. 1021-1027, (1990)

[13]

Fraser H.M., Sandow J., Cowen G.M., Lumsden M.A., Haining R., Smith S.K., Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis, Fertil. Steril, 54, pp. 61-68, (1990)

[14]

Franssen A. M.H. W., Kauer F.M., Chadha D.R., Zijlstra J.A., Rolland R., Endometriosis treatment with gonadotropin-releasing hormone agonist buserelin, Fertil. Steril, 51, pp. 401-408, (1989)

[15]

Henzl M.R., Corson S.L., Moghissi K., Buttram V.C., Berqvist C., Jacobson J., Administration of nasal nafarelin as compared with oral danazol for endometriosis, N. Engl. J. Med, 318, pp. 485-489, (1988)

[16]

Kennedy S.H., Williams I.A., Brodribb J., Barlow D.H., Shaw R.W., A comparison of nafarelin acetate and danazol in the treatment of endometriosis, Fertil. Steril, 53, pp. 998-1003, (1990)

[17]

Halme J., Hammond M.G., Hulka J.F., Shailaja G.R., Talbert L.M., Retrograde menstruation in healthy women and in patients with endometriosis, Obstet. Gynecol, 64, pp. 151-159, (1984)

[18]

Clement P.B., Endometriosis, lesions of the secondary mullerian system and pelvic mesothelial proliferation, Blaustein's Pathology of the Female Cenital Tract, 3rd edn, pp. 516-559, (1987)

[19]

Steele R.W., Dmowski W.P., Marmer D.J., Immunologic aspects of human endometriosis, Am. J. Reprod. Immunol, 6, pp. 33-36, (1984)

[20]

Oosterlynck D., Cornillie F.J., Waer M., Vandeputte M., Koninckx P.R., Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium, Fertil. Steril, 56, pp. 45-51, (1991)

← 1 2 3 4 5 →